Selected article for: "following infection and SARS spike"

Author: Speer, Claudius; Morath, Christian; Töllner, Maximilian; Buylaert, Mirabel; Göth, Daniel; Nusshag, Christian; Kälble, Florian; Schaier, Matthias; Grenz, Julia; Kreysing, Martin; Reichel, Paula; Hidmark, Asa; Ponath, Gerald; Schnitzler, Paul; Zeier, Martin; Süsal, Caner; Klein, Katrin; Benning, Louise
Title: Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
  • Cord-id: 5mgg0npj
  • Document date: 2021_8_17
  • ID: 5mgg0npj
    Snippet: Seroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients. We performed a dual-center cohort study comparing three different groups: 25 unvaccinated hemodialysis patients after PCR-confirmed COVID-19 (Group 1), 43 hemodialysis patients after two-time BNT162b2 vaccination witho
    Document: Seroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients. We performed a dual-center cohort study comparing three different groups: 25 unvaccinated hemodialysis patients after PCR-confirmed COVID-19 (Group 1), 43 hemodialysis patients after two-time BNT162b2 vaccination without prior SARS-CoV-2 infection (Group 2), and 13 single-dose vaccinated hemodialysis patients with prior SARS-CoV-2 infection (Group 3). Group 3 consists of seven patients from Group 1 and 6 additional patients with sera only available after single-dose vaccination. Anti-S1 IgG, neutralizing antibodies, and antibodies against various SARS-CoV-2 protein epitopes were measured 3 weeks after the first and 3 weeks after the second vaccination in patients without prior SARS-CoV-2 infection, 6 weeks after the onset of COVID-19 in unvaccinated patients, and 3 weeks after single-dose vaccination in patients with prior SARS-CoV-2 infection, respectively. Unvaccinated patients after COVID-19 showed a significantly higher neutralizing antibody capacity than two-time vaccinated patients without prior COVID-19 [median (IQR) percent inhibition 88.0 (71.5–95.5) vs. 50.7 (26.4–81.0); P = 0.018]. After one single vaccine dose, previously infected individuals generated 15- to 34-fold higher levels of anti-S1 IgG than age- and dialysis vintage-matched unvaccinated patients after infection or two-time vaccinated patients without prior SARS-CoV-2 infection with a median (IQR) index of 274 (151–791) compared to 18 (8–41) and 8 (1–21) (for both P < 0.001). With a median (IQR) percent inhibition of 97.6 (97.2–98.9), the neutralizing capacity of SARS-CoV-2 antibodies was significantly higher in single-dose vaccinated patients with prior SARS-CoV-2 infection compared to other groups (for both P < 0.01). Bead-based analysis showed high antibody reactivity against various SARS-CoV-2 spike protein epitopes after single-dose vaccination in previously infected patients. In conclusion, single-dose vaccination in previously infected dialysis patients induced a strong and broad antibody reactivity against various SARS-CoV-2 spike protein epitopes with high neutralizing capacity.

    Search related documents:
    Co phrase search for related documents
    • ache muscle and local response: 1
    • ache muscle headache and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome coronavirus and additional patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome coronavirus and local response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute respiratory syndrome coronavirus and longitudinal cohort: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
    • acute respiratory syndrome coronavirus and longitudinal cohort study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome coronavirus and low antibody response: 1, 2, 3, 4, 5
    • acute respiratory syndrome coronavirus and low humoral response: 1, 2
    • acute respiratory syndrome coronavirus and low seroconversion rate: 1
    • acute respiratory syndrome coronavirus and low vaccine response: 1
    • acute respiratory syndrome coronavirus and luminex corporation: 1
    • acute respiratory syndrome coronavirus and luminex platform: 1, 2
    • acute respiratory syndrome coronavirus type and longitudinal cohort: 1, 2
    • acute respiratory syndrome coronavirus type and longitudinal cohort study: 1, 2
    • additional patient and longitudinal cohort: 1
    • additional patient and longitudinal cohort study: 1
    • local response and low antibody response: 1
    • local response and low vaccine response: 1
    • local response low and low antibody response: 1